Key result
The primary cardiomyopathy of systemic sclerosis was associated with a greater long-term incidence of death or major cardiovascular events.
Why the study?
Cardiac disease in systemic sclerosis (SSc) can be primary or secondary, but the prevalence, CMR features, and prognostic implications of primary SSc cardiomyopathy are unknown.
Does the presence of primary cardiomyopathy of systemic sclerosis on CMR predict death or major adverse cardiac events in patients with systemic sclerosis?
Cohort (n=130)
Does the presence of primary cardiomyopathy of systemic sclerosis on CMR predict death or major adverse cardiac events in patients with systemic sclerosis?
Answers are grounded in this paper and cite their sources.
Primary cardiomyopathy of systemic sclerosis is present in 21% of SSc patients undergoing CMR and is independently associated with a twofold increased risk of death or major adverse cardiac events.
AIMS: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to other disease manifestations of SSc. The prevalence of the primary cardiomyopathy of SSc is unknown. Cardiovascular magnetic resonance (CMR) imaging can help accurately determine the presence and cause of cardiomyopathy. We aimed to investigate the prevalence, the CMR features, and the prognostic implications of the primary cardiomyopathy of SSc. METHODS AND RESULTS: We conducted a retrospective cohort study of consecutive patients with SSc who had a clinical CMR for suspected cardiac involvement. We identified the prevalence, the CMR features of the primary cardiomyopathy of SSc, and its association with the long-term incidence of death or major adverse cardiac events (MACEs): heart failure hospitalization, ventricular assist device implantation, heart transplantation, and sustained ventricular tachycardia. Of 130 patients with SSc, 80% were women, and the median age was 58 years. On CMR, 22% had an abnormal left ventricular ejection fraction, and 40% had late gadolinium enhancement (LGE). The prevalence of the primary cardiomyopathy of SSc was 21%. A third of these patients had a distinct LGE phenotype. Over a median follow-up of 3.6 years after the CMR, patients with the primary cardiomyopathy of SSc had a greater incidence of death or MACE (adjusted hazard ratio 2.01; 95% confidence interval 1.03-3.92; P = 0.041). CONCLUSION: The prevalence of the primary cardiomyopathy of SSc was 21%, with a third demonstrating a distinct LGE phenotype. The primary cardiomyopathy of SSc was independently associated with a greater long-term incidence of death or MACE.
No takes yet. Share an insight, caveat, or question.
Chhikara et al. (2023) conducted a cohort in Systemic sclerosis (SSc) (n=130). Primary cardiomyopathy of SSc vs. Patients without primary cardiomyopathy of SSc was evaluated on Death or major adverse cardiac events (MACEs) (HR 2.01, 95% CI 1.03-3.92, p=0.041). The primary cardiomyopathy of systemic sclerosis was associated with a greater long-term incidence of death or major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: